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INTRODUCTION
Holoprosencephaly (HPE) is the most common congenital forebrain
defect in humans. It results from failed or incomplete forebrain
cleavage between days 18 and 28 of gestation (Dubourg et al., 2007;
Marcorelles and Laquerriere, 2010).
The clinical presentation of HPE is remarkably variable, and the
severity of the defects observed is evenly distributed along the HPE
spectrum. The etiology is very complex and heterogeneous,
involving chromosomal anomalies, multiple malformation
syndromes and environmental factors. Fourteen genes are known
to be involved in non-syndromic human HPE (SHH, ZIC2, SIX3,
TGIF, DISP1, NODAL, GLI2, PTCH1, TDGF1, FOXH1, FGF8,
GAS1, DLL1 and CDON), but they explain only 30% of HPE cases
(Mercier et al., 2011). All mutations are found in the heterozygous
state in HPE patients, and most are loss-of-function mutations
(Dubourg et al., 2004; Arauz et al., 2010; Ribeiro et al., 2010; Roessler
and Muenke, 2010; Bae et al., 2011; Dupé et al., 2011). The
correlation between the HPE phenotype and genotype is poor, and
both sporadic cases and pedigrees display the extensive HPE
phenotype variability. This suggests that heterozygous mutations
of HPE genes might be insufficient to produce severe anomalies,
and that HPE is the consequence of a complex interplay of
developmental, genetic and environmental factors. To date, given
the relatively low percentage of cases for which causative mutations
have been identified, additional studies are undoubtedly warranted.
From animal model studies, multifactorial inheritance disorder
has been proposed to contribute to the phenotype heterogeneity
of the disorder. For example, heterozygous mutation of several genes
belonging to the same or different pathways could lead to
phenotypic heterogeneity. Mouse models have provided evidence,
by implicating either one or two different signaling pathways
[Nodal+/−;Smad2+/− (Nomura and Li, 1998); Cdo−/−;Boc−/− (Zhang
et al., 2011); and Chrd−/−;Nodal+/− (Yang et al., 2010)]. The genetic
background also plays an important role in determining the severity
of the phenotype, suggesting the existence of modifier genes (Cole
and Krauss, 2003; Krauss, 2007; Geng et al., 2008; Pei and Feldman,
2009). Furthermore, observation of some HPE patients with two
different genetic alterations are consistent with a multigenic process
(Mercier et al., 2011; Ming and Muenke, 2002). Thus, the diversity
of combinations of mutations in HPE genes and/or modifier genes
belonging to different pathways could contribute to the wide
spectrum of HPE phenotypes.
HPE genes belong to various different signaling pathways
regulating forebrain development, including the Hedgehog (HH),
NODAL, BMP and FGF pathways. The role of these pathways
during forebrain development has been extensively studied,
especially the SHH and NODAL pathways, the two major pathways
implicated in the pathogenesis of HPE (Roessler and Muenke, 2010).
However, the interactions between these pathways, in terms of
spatial and temporal regulation during the development of HPE,
need to be clarified.
The NODAL signaling pathway has been implicated in cases
of human HPE with or without congenital heart defects and/or
left-right disturbances (Roessler et al., 2008; Roessler et al., 2009).
NODAL is a transforming growth factor β (TGF-β)-related
signaling molecule that is essential during the initiation of
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SUMMARY
Holoprosencephaly (HPE) is a common congenital defect that results from failed or incomplete forebrain cleavage. HPE is characterized by a wide
clinical spectrum, with inter- and intrafamilial variability. This heterogeneity is not well understood and it has been suggested that HPE involves a
combination of multiple gene mutations. In this model, several mutated alleles or modifying factors are presumed to act in synergy to cause and
determine the severity of HPE. This could explain the various clinical phenotypes. Screening for HPE-associated genes in humans suggests the
involvement of NODAL or SHH signaling, or both. To test this multigenic hypothesis, we investigated the effects of chemical inhibition of these two
main HPE signaling pathways in a chick embryo model. SB-505124, a selective inhibitor of transforming growth factor-B type I receptors was used
to inhibit the NODAL pathway. Cyclopamine was used to inhibit the SHH pathway. We report that both inhibitors caused HPE-like defects that were
dependent on the drug concentration and on the developmental stage at the time of treatment. We also investigated double inhibition of NODAL
and SHH pathways from the onset of gastrulation by using subthreshold inhibitor concentrations. The inhibitors of the NODAL and SHH pathways,
even at low concentration, acted synergistically to promote an HPE-like phenotype. These findings support the view that genetic heterogeneity is
important in the etiology of HPE and may contribute to the phenotypic variability.
NODAL and SHH dose-dependent double inhibition
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gastrulation. NODAL signals act in the formation of mesoderm
and are required later for correct positioning of the
anteroposterior axis, midline patterning and left-right
specification (Iannaccone et al., 1992; Zhou et al., 1993; Conlon
et al., 1994; Lowe et al., 2001; Roessler et al., 2008; Roessler et al.,
2009). The NODAL signaling pathway has been extensively
studied during cleavage and blastula stages in zebrafish; NODAL
acts in a dose-dependent and time-dependent manner during the
mid-to-late blastula stage to specify most mesodermal and
endodermal cell types (Hagos and Dougan, 2007; Gritsman et al.,
2000). The total absence of NODAL is embryonically lethal,
whereas a hypomorphic allele of Nodal or chemical inactivation
results in anterior patterning defects including cyclopia in mice,
zebrafish and Xenopus (Lowe et al., 2001; Vincent et al., 2003;
Hagos and Dougan, 2007; Luxardi et al., 2010). These defects are
strictly dependent on the degree of NODAL inactivation and on
the embryonic stage. Consistent with the importance of this
pathway during development, inactivation at early stages leads to
very severe phenotypes, and the critical time-window of
requirement for NODAL activity during forebrain formation is
difficult to define (Shen, 2007; Luxardi et al., 2010).
Disruption of SHH signaling is a common major event in the
development of HPE. Mice lacking SHH function have a severe
HPE-like phenotype involving the absence of ventral forebrain
structures and cyclopia (Chiang et al., 1996). Studies with model
organisms demonstrate that SHH produced by the prechordal
mesendoderm is required for initiating the development of the
midline of the forebrain and the midface (Rubenstein and Beachy,
1998; Muenke and Beachy, 2000; Kiecker and Niehrs, 2001).
Abnormal activity of the SHH signaling pathway at particular
periods of embryonic development might account for the
phenotypical spectrum of HPE (Cordero et al., 2004). There is a
progressive mechanism whereby SHH produced by one midline
structure induces Shh expression in successive midline structures.
Most human HPE genes either encode components of the SHH
pathway, or directly or indirectly affect Shh expression in either
the prechordal mesendoderm or the developing ventral forebrain
(Hu and Helms, 1999; Marcucio et al., 2005; Dubourg et al., 2007;
Geng and Oliver, 2009).
SHH and NODAL signals interact and Hedgehog signaling acts
downstream from NODAL activity to pattern the ventral
telencephalon (Müller et al., 2000; Rohr et al., 2001). Indeed,
expression of Shh is severely reduced in mutants for the NODAL
pathway, particularly in anterior regions (Strähle et al., 1997; Hagos
and Dougan, 2007). The mechanisms by which NODAL signaling
regulates SHH activity in axial tissues have yet to be determined,
but NODAL signals can cell-autonomously promote floorplate-
specific expression of Shh (Müller et al., 2000). The interaction
between SHH and NODAL pathways takes place during
gastrulation as the floorplate is established. The description of
heterozygous mutations of SHH and TGIF (which interact with
TGF-β-activated Smad proteins) in the same HPE patient is further
evidence for there being interaction between SHH and NODAL
(Nanni et al., 1999). However, it is not known whether the
association of effects in each of these two pathways can cause HPE.
Here, we studied partial chemical inhibition of these two
pathways during chick forebrain development. Our aim was to
evaluate the interaction between NODAL and SHH pathways and
to investigate the HPE multiple-genetic process in an animal model
using a dose- and time-dependent approach. We demonstrate that
phenotypic severity was dependent on the stage of treatment and
on the concentration of the chemical inhibitors of the NODAL and
SHH signaling pathways. Subthreshold concentrations of the two
inhibitors in combination caused severe effects. These
investigations show that the partial inhibition of two pathways can
have a cumulative effect in determining an HPE-like phenotype
and support a genetic heterogeneity hypothesis for HPE.
RESULTS
Inactivation of the NODAL signaling pathway from the stage of
gastrulation onset leads to severe forebrain defects
The chemical inhibitor SB-505124 was used to inactivate NODAL
signaling (Hagos and Dougan, 2007). This compound has been used
previously to dissect the complex pathway of the TGF-β superfamily
and has been validated for inhibition of the activin receptor-like
kinase (ALK)4/5/7-dependent activation (DaCosta Byfield et al.,
2004).
To analyze the effect of SB-505124 on chick forebrain during its
formation, we studied three molecular markers: Pax6, Shh and
Nkx2.1. The Pax6 homeobox gene is specifically expressed in
developing optic vesicles, making it a good indicator of eye defects,
from hypotelorism to cyclopia, one of the main features of the HPE
spectrum (Incardona et al., 1998). Shh and Nkx2.1 are ventral
dmm.biologists.org538
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TRANSLATIONAL IMPACT
Clinical issue
Holoprosencephaly (HPE), a remarkably common human birth defect, is
caused by a failure to form the midline of the forebrain and midface. Its clinical
presentation is extremely variable, ranging from alobar HPE (where there is a
complete failure to divide the forebrain) to microform (where there are mild
craniofacial features but no forebrain defects). Various craniofacial defects
(from none to cyclopia) and other extra-craniofacial defects are observed. HPE
is probably caused by both environmental and genetic factors; with respect to
the latter, heterozygous mutations in components or regulators of the Sonic
Hedgehog (SHH) signaling pathway are often associated. The phenotypic
heterorogeneity seen in carriers of SHH pathway mutations, ranging from no
clinical manifestation to alobar HPE, implicates other modifier genes in
forebrain development.
Results
In addition to SHH signaling, several other pathways regulate forebrain
development, such as the NODAL pathway. Here, the authors established a
chick embryo culture model to investigate the effects of chemical inhibition of
SHH and NODAL pathways during forebrain development. They report that
inhibition of either pathway caused HPE-like defects with phenotypic
variability. Inhibition of both pathways using subthreshold inhibitor
concentrations acted synergistically to promote severe HPE-like phenotypes.
These findings support the view that genetic heterogeneity plays a key role in
HPE etiology and contributes to the phenotypic variability.
Implications and future directions
Because HPE arises from a complex interplay of developmental, genetic and
environmental factors, it is difficult to study the condition using genetic
approaches in a mouse model. By comparison, it is simpler to use cultured
chick embryos for testing the multi-genetic hypothesis of human HPE and for
validating new candidate genes. The identification of new modifier genes by
whole exome sequencing will aid in the understanding HPE etiology, and
provide new direction to mechanistic studies in the chick and in other model
organisms.
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markers of the developing forebrain (Crossley et al., 2001): they are
targets of NODAL signaling during forebrain development and are
specifically downregulated in animal models of HPE (Müller et al.,
2000; Rohr et al., 2001).
We used ex ovo chick embryo cultures (so-called roller cultures)
to test the effects of NODAL signaling inhibition during early
brain formation (Dupé and Lumsden, 2001). The NODAL
signaling pathway was inactivated in whole embryos from the
onset of gastrulation (between stage 4 and stage 6 in the chick)
until the primary regionalization of the forebrain (stage 12). The
NODAL pathway is required during early gastrulation (Shen,
2007), so a concentration and a stage of treatment allowing
gastrulation to occur but causing a forebrain phenotype had to
be determined.
Whole chick embryos (n=317) from stage 4 to stage 6 were
exposed to one of a series of SB-505124 concentrations: 10, 25, 50
or 75  μM. At least five different experiments were run for each
condition. Because we clearly observed a phenotypic heterogeneity,
we individualized three distinct phenotypes on the basis of the
morphology and gene expression (arbitrarily classified as categories
1, 2 and 3) (Fig. 1A).
At the onset of the gastrulation (Stage 4+), most embryos (70%)
treated with 25 μM SB-505124 were similar to controls (DMSO-
treated embryos) in terms of morphology and expression of Pax6,
Shh and Nkx2.1 (Fig. 1A, category 1). However, 30% of the embryos
displayed a mild phenotype, involving forebrain hypoplasia (Fig. 1A,
category 2). In these category 2 embryos, optic vesicles were
formed, as shown by in situ hybridization for Pax6, but they were
in a more ventral position than in controls. They were fused only
in rare cases. Importantly, expression of both Nkx2.1 and Shh was
specifically downregulated in the rostral diencephalic ventral
midline (Fig. 1A, arrowheads) similar to that described in several
HPE models (Allen et al., 2007; Higashiyama et al., 2007), including
hypomorph mutants for NODAL signaling (Lowe et al., 2001;
Vincent et al., 2003). At SB-505124 concentrations of 50 μM or
75 μM administered from stage 4+ (Fig 1B), forebrain defects were
severe (category 3) and characterized by anterior truncation with
non-fused neural folds (Fig. 1Ad, T*), no formation of optic vesicles
and downregulation of the expression of Shh and Nkx2.1 in the
rostral midline (Fig.  1Ah,Al). This category 3 phenotype was
observed in 59% and 77% of the embryos treated with 50 μM and
75 μM, respectively, from stage 4+.
We tested the response of chick embryos to SB-505124 according
to the stage of treatment. The category 3 phenotype was frequent
among embryos treated with 50 μM from stage 4 (68%) or 4+ (59%)
(Fig 1C), but this severe phenotype was significantly less frequent
when the treatment was started at stage 5 (10%). After stage 5,
severe phenotypes were not observed: category 2 was more frequent
for stage 5 (59%) and category 1 for stage 6 (63%).
In conclusion, category 3 (severe) phenotypes were mainly
observed at a drug concentration over 25 μM initiated at stages 4
or 4+, just at the onset of gastrulation.
Cyclopamine causes progressive cyclopia in a dose-dependent
manner
Cyclopamine is a well-characterized chemical inhibitor of the SHH
signaling pathway (Cooper et al., 1998; Incardona et al., 1998): it
inhibits the morphogenetic activity of the SHH pathway by binding
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Fig. 1. NODAL signal inhibition by SB-505124 treatment leads to severe
forebrain defects; the dose-response relationship is nonlinear. (A)Ventral
views of chick embryo heads at stage 12. Control embryos (n=150) were
treated with DMSO (Aa, Ae, Ai). Other embryos were treated with one of a
series of SB-505124 concentrations (10-75 μM) between stage 4 and stage 6
(n=317). Resulting phenotypes were classified into three categories according
to morphology and in situ hybridization for Pax6 (n=111) (Aa-Ad), Shh (n=107)
(Ae-Ah) and Nkx2.1 (n=99) (Ai-Al). The order of increasing severity was:
category 1, category 2 and category 3. Arrowheads show the downregulation
of Shh (Ag) and Nkx2-1 (Ak) expression in the ventral forebrain. (B)Distribution
of the phenotypes of stage 4+ embryos treated with one of a series of SB-
505124 concentrations: 10 μM (n=15), 25 μM (n=20), 50 μM (n=22) or 75 μM
(n=26). (C)Distribution of the phenotypes of embryos treated with 50 μM SB-
505124 starting at various stages: from stage 4 (n=40), stage 4+ (n=22), stage 5
(n=29) and stage 6 (n=16). OV, optic vesicles; T, telencephalon; T*, non-fused
telencephalon; Cat, category.
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to and preventing activation of the transmembrane protein,
Smoothened (Smo) (Chen et al., 2002; Lipinski et al., 2008). First,
as for SB-505124, we identified the stages and concentrations at
which cyclopamine caused HPE-like defects.
Chick embryos were exposed to cyclopamine concentrations
between 0.006 μM and 2.5 μM at stage 4+ (Fig. 2). After 24 hours
of culture, the embryos were individually scored for morphological
abnormalities and Pax6 expression. A phenotypic index was
calculated and the phenotypes were classified into three categories,
from normal embryo, category I to embryos with fused optic
vesicles, category III.
All embryos treated with 0.006 μM of cyclopamine at stage 4+,
showed normal head development (category I). Normal head
development was similarly observed in 85% of the embryos treated
with 0.025 μM cyclopamine. The other 15% showed partial fusion
of the optic evaginations ventrally, as confirmed by analysis of Pax6
expression. This was defined as the category II phenotype (Fig. 2A).
At a higher cyclopamine concentration (0.5 μM), we observed a
new phenotype (category III) characterized by optic vesicle fusion,
from partial fusion to cyclopia, associated with an elongated
forebrain (35%) (Fig.  2A). At the highest concentration of
cyclopamine tested (2.5  μM), 75% of the embryos displayed a
category III phenotype (Fig. 2B).
To determine when Shh-dependent forebrain patterning occurs,
embryos were treated with 2.5 μM cyclopamine at various stages.
Exposure at stage 5 or 6 resulted in a high proportion of cyclopic
embryos (data not shown). However, following treatment with
2.5  μM cyclopamine starting at stage 7, none of the embryos
developed cyclopia.
These experiments describe the relationship between cyclopia
and both the stage of treatment and cyclopamine concentration.
They confirms the involvement of SHH in the ventralization of the
forebrain during early gastrulation (stages 5 and 6) (Pera and Kessel,
1997). These experiments also identified a subthreshold
concentration (0.006  μM) of cyclopamine that has no apparent
morphological effect on either head development or fusion of the
optic vesicles.
Combined partial inhibition of SHH and NODAL signals leads to
cyclopic embryos
We studied the effects of combined treatment with the inhibitors
of the NODAL and SHH signaling pathways, at subthreshold
concentrations. SHH signal inactivation between stages 4 and 6
was required to obtain cyclops (see above). NODAL inactivation
before stage 5 was required to cause a forebrain phenotype.
Therefore, we used stage 4+ embryos for these experiments.
Stage 4+ chick embryos (total n=187) in roller cultures were
exposed to 0.006 μM cyclopamine or 25 μM SB-505124 or both.
Pax6 expression was studied in these embryos.
We defined three new phenotypic categories (I* to III*) to score
the degree of fusion of optic vesicles. These categories are similar
to those defined for cyclopamine treatment, but include progressive
forebrain hypoplasia (Fig. 3A). Thus, category I* was defined as
embryos with non-fused expression of Pax6 in the optic vesicles
(Fig.  3Aa), and included morphologically normal embryos and
embryos with slightly ectopic optic vesicles. Category II* (Fig. 3Ab)
embryos displayed a phenotype with ectopic optic vesicles (ventral
position) with continuous expression of Pax6. Category III* was a
severely affected phenotype with partial or complete fusion of the
optic vesicle (cyclopia) associated with marked forebrain hypoplasia
(Fig. 3Ac,Ad). We scored the severity of the phenotypes after the
three treatments (Fig. 3B).
The most severe phenotype, category III*, was never observed
following treatment with 0.006 μM cyclopamine alone, and only 6%
of these embryos displayed a category II* phenotype (Fig.  3B).
Following treatment with 25 μM SB-505124 alone, 7% of the embryos
were category II* and 5% category III*. About 20% of the embryos
subjected to the double treatment were category II* and 14% category
III*. The proportions of categories II* and III* differed significantly
between combined and single inactivation groups (P=4×10−4).
Therefore, combination of the two inhibitors at subthreshold
concentrations caused more severe midline abnormalities than
either inhibitor alone. These findings suggest that abnormal
NODAL and SHH signals interact to produce various HPE-
spectrum phenotypes. Similar double treatment started at stage 5
(n=49) or stage 6 (n=20) did not have a greater effect than single
treatments (data not shown).
DISCUSSION
The molecular basis for the variable expressivity and reduced
penetrance of HPE has not yet been identified. However, the
dmm.biologists.org540
Holoprosencephaly and genetic heterogeneityRESEARCH REPORT
Fig. 2. Cyclopamine causes cyclopia in a dose-dependent manner.
(A)Ventral views of chick embryo heads at stage 12. Three phenotypes were
distinguished morphologically. Pax6 mRNA was used as a marker for optic
vesicles (n=70). The order of increasing severity was: category I, category II
and category III. (B)Distribution of the phenotypes observed for embryos
treated at stage 4+ by one of a series of concentrations of cyclopamine:
0.006 μM (n=30), 0.025 μM (n=38), 0.5 μM (n=48) or 2.5 μM (n=33). OV, optic
vesicles; OV*, single optic vesicle; T, telencephalon; Cat, category. Brackets
highlight the distance between optic vesicles.
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digenism described in animal models for HPE supports the
existence of a heterogeneous and multigenic mechanism in some
human cases, in which the penetrance and expressivity of
heterozygous loss-of-function mutations can be modulated by one
or more other mutations (Mercier et al., 2011; Roessler et al., 2012).
Here, we report the development of an animal model in which
various signaling pathways can be simultaneously and partially
inhibited. We used this model to inactivate the NODAL and SHH
pathways, both major pathways implicated in human HPE, during
forebrain development.
In knockout models, the loss of NODAL signaling blocks
gastrulation and is embryonically lethal (Lowe et al., 2001).
However, analysis of Nodal-insufficient embryos revealed that
although the gastrulation takes place, eye field and forebrain fail
to develop properly and a HPE-like phenotype develops (Lowe et
al., 2001; Vincent et al., 2003; Andersson et al., 2006; Yang et al.,
2010). Here, we used the ALK4/5/7 receptor inhibitor, SB-505124,
for partial inhibition of the NODAL pathway during chick
development. It was previously shown that this drug added to
developing zebrafish at various stages of development causes a
spectrum of phenotypes, including cyclopia, that are phenocopies
of NODAL component mutants (Hagos and Dougan, 2007). Even
though multiple ligands can activate the ALK4/5/7 receptors, our
phenotypes resemble those resulting from reductions in nodal-
related gene function (Vincent et al., 2003; Andersson et al., 2006;
Yang et al., 2010). This suggests that the other activin-like ligands
are either not implicated during the stages we examined or act
downstream of Nodal signals.
It has not yet been established when NODAL signals contribute
to the anterior midline specification in chick embryos. In our
experiments, embryos were treated in roller culture with various
concentrations of SB-505124 at the onset of gastrulation. The
severity of the resulting defects in forebrain development depended
both on the concentration of the inhibitor and the stage at which
treatment started. NODAL is essential for gastrulation through the
regulation of several major genes; however, the difficulty was to
find a window and concentration at which the inhibition was strong
enough to induce an HPE-like phenotype (category 2) without
causing a phenotype that was too severe (category 3). During our
SB-505124 treatment, analysis of Pax6 expression did not reveal
any typical cyclopic phenotype, whereas in situ hybridization
evidenced reduced, or loss of, Shh and Nkx2.1 expression in the
rostral midline region. Despite the lack of the typical HPE
phenotype, this absence of expression of Shh and Nkx2.1 at the
anterior boundary of expression support the idea that these
category 2 embryos display a HPE-like phenotype (Lowe et al., 2001;
Anderson et al., 2002; Vincent et al., 2003; Allen et al., 2007;
Higashiyama et al., 2007). The crucial stage for NODAL signaling
in our model is before stage 5, which is consistent with the
description of NODAL expression: Nodal is expressed in the
middle three-quarters of the primitive streak, excluding Hensen’s
node, up to stage 5; Nodal expression then ceases in the midline
(Lawson et al., 2001).
Cyclopamine treatment caused, in a dose-dependent manner,
fusion of the optic vesicles up to cyclopia, the most severe typical
craniofacial defect in HPE. Interestingly, in HPE patients with
altered SHH signaling, midline malformation ranges from
hypotelorism to complete cyclopia (Muenke and Beachy, 2000). The
features of our model are consistent with the demonstration by
Cordero et al. of a relationship between the timing of Hedgehog
disruption and the severity of the facial phenotype (Cordero et al.,
2004). Interestingly, embryos subjected to cyclopamine treatment
starting as late as stage 7 developed a cyclopic phenotype. This is
in agreement with the continuous expression of Shh throughout
the node at stage 4 and subsequently in the prechordal
mesendoderm at stage 7, the crucial structure for ventral forebrain
patterning (Crossley et al., 2001).
We investigated whether minor defects in NODAL and SHH
pathways can synergize to produce HPE disorders. Our preliminary
experiments indicated that stage 4+ embryos were suitable for these
experiments for two reasons. First, SB-505124 had the largest effect
on head development when administrated at stage 4 and 4+.
Second, the stage 4+ is easy to distinguish, but also very transient,
leading to less variability in the results. We used concentrations of
inhibitors that in isolation did not cause any severe forebrain defect
or severe optic vesicle fusion (25  μM SB-505124 and 0.006  μM
cyclopamine). The proportion of embryos with ventralized optic
vesicles (category II*) and fusion (category III*) was substantially
higher following double treatment than single treatment. An optic
vesicle phenotype was observed in 34% of double-treated embryos,
and optic vesicle fusion up to cyclopia in 15%. This effect was not
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Fig. 3. Simultaneous partial inhibition of NODAL and SHH causes HPE-like
anterior neural defects in chick embryo. (A)Ventral views of chick embryo
heads at stage 12. Embryos were treated with SB-505124 (25 μM) and
cyclopamine (0.006 μM) at stage 4+ (n=187). Three phenotypes were
distinguished using Pax6 in situ hybridization. The order of increasing severity
was: category I*, category II* and category III*. (B)Phenotype distributions
among embryos treated with cyclopamine (n=52), SB-505124 (n=59) or both
(n=76) at stage 4+. The asterisks show the significant cumulative effect of the
double treatment leading to the HPE-like phenotype (*P=4×10−4). OV, optic
vesicles; OV*, single optic vesicle; T, telencephalon; Cat, category.
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reproduced when embryos were treated slightly later, at stage 5.
These experiments show that minor inhibition of both SHH and
NODAL pathways can lead to abnormal development of the
forebrain midline, whereas similar inhibition of one or other in
isolation does not. The penetrance of the phenotypes obtained was
incomplete and variable, which is a common feature of most HPE
models described (Lowe et al., 2001; Allen et al., 2007; Zhang et
al., 2011; Cordero et al., 2004).
Cyclopamine and SB-505124 single treatments as a combination
of both inhibitors generated phenotypic heterogeneity. This
variability, from no morphological anterior deficit to severe anterior
truncation, is greater with intermediate concentration of inhibitors
(50 μM for SB-505124 and 0.5 μM for cyclopamine at stage 4+); it
reflects the importance of the quantitative requirement of the level
of NODAL and SHH signaling during forebrain development.
NODAL and SHH signaling are decisive in forebrain fate
determination and the corresponding genes are expressed
simultaneously in the primitive streak and the prechordal plate.
The mechanism by which NODAL signaling regulates SHH activity
during gastrulation has yet to be determined. However, several
studies have indicated that the NODAL pathway regulates ventral
forebrain patterning through SHH-independent mechanisms (Rohr
et al., 2001; Monuki, 2007). SHH might have to reach a threshold
concentration to ensure proper forebrain development (Young et
al., 2010). The dose- and stage-dependent relationship we observe
here is consistent with a threshold effect: slightly reduced NODAL
signaling might cause a small downregulation of SHH, which
produces a HPE phenotype only when associated with another
small decrease in SHH signaling.
Overall, we demonstrate that weak inhibition of two signaling
pathways, one downstream of the other, can lead to an HPE-like
phenotype. A similar interaction between NODAL and BMP has
also been demonstrated in forebrain development (Yang et al.,
2010). Therefore, several independent genetic events influencing
different signaling pathways involved in forebrain development,
acting at the same or different embryonic stages, can cause the HPE
phenotype, most probably through regulation of the main HPE
signaling pathway, SHH. This could be the basis for the phenotypic
heterogeneity observed in families segregating mutations in SHH.
This is coherent with the systematic decrease of Shh in animal
models with partial inhibitions of various signaling pathways
(Krauss, 2007; Fernandes and Hébert, 2008; Geng and Oliver, 2009;
Yang et al., 2010). These observations are consistent with a ‘multi-
signaling pathways-hit’ model. It is likely that as-yet unidentified
polymorphisms contribute to the hypomorphic effects involved in
HPE. Further work with whole exome sequencing would help
confirm this theory.
MATERIALS AND METHODS
Roller-tube culture and chemical inhibition in chick
Fertile hens’ eggs were incubated in a humidified room at 38°C.
The embryos were staged according to Hamburger and Hamilton
(Hamburger and Hamilton, 1992). They were collected at stages 4,
4+, 5 and 6 and cultured as described elsewhere (Dupé and
Lumsden, 2001). Five embryos, folded and sealed along the
longitudinal axis, were transferred to a 5-ml plastic bottle
containing 500 μl of Liebovitz medium. The bottles were placed
on a roller apparatus rotating at 30 revolutions/minute, inclined at
an angle of about 10° in a 38°C incubator. Development was then
allowed to proceed for 24 hours. The embryos were treated with
the following compounds: cyclopamine (Sigma) from a stock
solution of 1  mg/ml in 2-hydroxypropyl-β-cyclodextrin (HBC,
Sigma); and SB-505124 (Sigma-Aldrich), from a stock solution of
24 mg/ml in DMSO. No toxicity was observed up to 100 μM for
SB-505124 (DaCosta Byfield et al., 2004). Embryos were treated
with cyclopamine, SB-505124 or both included in the culture
medium continuously, starting from stage 4 to stage 6. Control
embryos were treated with DMSO (n=352) or HBC (n=115). In
our culture conditions, about 90% of the embryos were
morphologically normal; the only visible abnormalities in the other
10% were localized failures of neural tube closure. However, the
anatomical regionalization and gene expression of Pax6, Nkx2.1
and Shh were in all cases apparently normal.
Whole-mount in situ hybridization
Antisense digoxigenin-labeled riboprobes were used for whole-
mount in situ hybridization on chicken embryos as previously
described (Chapman et al., 2002). Plasmids carrying chick Shh,
Nkx2.1 and Pax6 were used as templates to generate the antisense
riboprobes.
Statistical analysis
Variables are expressed as numbers and percentages. Fisher’s exact
tests were used for comparisons. We used a type I error of 0.05,
by convention.
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